^
Association details:
| Biomarker: | AXL-L |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
Published date:
08/07/2021
Excerpt:
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC...Low AXL was predictive of relative improvement in PFS for cabozantinib versus everolimus.
DOI:
10.1186/s12885-021-08630-w
Trial ID:
